anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Bivalirudin
Trial phase: Phase 4
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Combination of Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Eligibility criteria:
Inclusion Criteria:

Minimum age: 12 years
Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema).
Diagnosis of impetiginous eczema.
Ability to understand the procedures of the protocol and follow the requirements during the course of the study.
Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial.

Exclusion Criteria:

Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician.
Participants with a history of hypersensitivity to any of the components of the medication being studied.
Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial.
Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease.
Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial.
Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.
Intervention: Bivalirudin
Trial phase: Phase 4
ATC code: B01AE06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](N)Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)O
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
Eligibility criteria:
Inclusion Criteria:

Minimum age: 12 years
Good general health confirmed by clinical history and a physical and skin examination (excluding area of skin with impetiginous eczema).
Diagnosis of impetiginous eczema.
Ability to understand the procedures of the protocol and follow the requirements during the course of the study.
Results of routine laboratory tests - hemogram with leukogram and platelet count, creatinine, glucose, sed. rate, IgE level and transaminases; along with plasma cortisol and adrenocorticotropic hormone (ACTH) levels prior to the start of the treatment. These results must all be within normal limits or not clinically relevant in order to be included in the trial.

Exclusion Criteria:

Pregnant participants or women of childbearing age who are not using birth control methods considered reliable by the attending physician.
Participants with a history of hypersensitivity to any of the components of the medication being studied.
Participants in whom the extent or severity of the lesions requires treatment of a different type than what is planned for this trial.
Participants who need any other type of topical or systemic medication during the trial that might affect the course of the disease.
Participants who have been treated with other topical medications during the 14-day period prior to the start of the trial.
Participants who have received systemic corticosteroids or any other immunosuppressant medication during the 28-day period prior to the start of the study.
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).

Normal saline:: Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
Eligibility criteria:
Inclusion Criteria:

Patient on invasive mechanical ventilation
New Onset (<48 hours) lobar or multilobar lung atelectasis based on CXR

Exclusion Criteria:

Asthma
Severe COPD (FEV1<30%)
Pneumothorax or massive pleural effusion, thought to be causing the atelectasis
Lobar atelectasis secondary to compressive tumor.
Severe hypoxemia (PaO2/FiO2 < 75)
Hemodynamic Instability
Cystic fibrosis patients
Allergy to DNase
Patients on Acetylcysteine
Pregnant women
Intervention: SODIUM CHLORIDE
Trial phase: Not Applicable
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 33
Group description: Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).

Hypertonic Saline: Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
Eligibility criteria:
Inclusion Criteria:

Patient on invasive mechanical ventilation
New Onset (<48 hours) lobar or multilobar lung atelectasis based on CXR

Exclusion Criteria:

Asthma
Severe COPD (FEV1<30%)
Pneumothorax or massive pleural effusion, thought to be causing the atelectasis
Lobar atelectasis secondary to compressive tumor.
Severe hypoxemia (PaO2/FiO2 < 75)
Hemodynamic Instability
Cystic fibrosis patients
Allergy to DNase
Patients on Acetylcysteine
Pregnant women
Intervention: Duloxetine
Trial phase: Phase 3
ATC code: N06AX21
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 150
Group description: Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsule, orally, once daily for 1 week after the treatment period.
Eligibility criteria:
Inclusion Criteria:

Suffers from a major depressive episode as the primary diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria.
The reported duration of the current major depressive episode is at least 3 months.

Exclusion Criteria:

Has 1 or more the following:

Any current psychiatric disorder other than major depressive disorder as defined in the DSM-IV-TR.
Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
Presence or history of a clinically significant neurological disorder (including epilepsy).
Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
Any Axis II disorder that might compromise the study.
Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale (MADRS) or has made a suicide attempt in the previous 6 months.
The current depressive symptoms of the patient are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
Has received electroconvulsive therapy within 6 months prior to Screening.
Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
Intervention: Lovaza
Trial phase: Phase 2
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 25
Group description: Treatment Arm
Eligibility criteria:
Inclusion Criteria:

Ages 10-19 years old
Fasting Triglyceride levels of 150-1000 mg/dl at the screening and baseline visit
Ability to swallow pills
Informed consent from a parent or legal guardian of minors or adult subject
Written assent from the adolescent to participate in the study
English or Spanish speaking

Exclusion Criteria:

Food Allergy to Fish or any components of the pills which includes alpha tocopherol, partially hydrogenated vegetable oils including soybean oils and gelatin and glycerol or corn oil, and iron oxide or iron oxide containing food color additives.
Pregnancy or positive urine pregnancy test for those females who have begun menstruating
Breast feeding
Alcohol Use: Patient is unable to abstain from alcohol use during the study. This will be assessed by asking the following questions: "During the past 30 days, on how many days did you have at least one drink of alcohol?"; "During the past 30 days, on how many days did you have 5 or more drinks of alcohol in a row, that is, within a couple of hours?"; "This study requires that you abstain from alcohol use during the course of the study. Do you think you can do this?"
Known Bleeding Disorder or Coagulopathy or treatment with anticoagulant medications or low platelet counts, abnormal PT, or PTT.
Significant cognitive or psychosocial disorder or medical illness that would limit participation in the trial.
Type 1 or 2 Diabetes or fasting glucose that is >=126 mg/dl
Liver disease or an ALT greater than 2 times upper limit of normal
Treatment with medications that affect triglyceride levels, including oral hypoglycemic agents or insulin.
Be currently taking the same oral contraceptive pills for less than the past three months or intend to change or discontinue prescription oral contraceptive pills used in the next seven months
Be currently taking any over-the-counter supplements that affect triglycerides or lipid metabolism including over the counter fish oil supplements.
Treatment for or diagnosis of a thyroid disorder or an elevated TSH level at baseline
Intervention: Naproxen
Trial phase: Phase 2
ATC code: G02CC02 | M01AE02 | M01AE52 | M01AE56 | M02AA12
SMILES: COc1ccc2cc([C@H](C)C(=O)O)ccc2c1
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 23
Group description: Naproxen 500 mg capsule
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for surgical removal of one partial or complete impacted mandibular third molar.
Provision of signed informed consent.

Exclusion Criteria:

History of somatic disease/condition, which may interfere with the objectives for the study, as judged by the investigator.
Clinically significant illness or clinically relevant trauma within the 2 weeks prior to the administration of the investigational product, as judged by the investigator.
A family history of short QT syndrome (SQTS) or sudden cardiac death (SCD) amongst first degree relatives
Patients with a body temperature >37.5°C at Visit 2, before start of surgical procedures
Intervention: Raltegravir
Trial phase: Not Applicable
ATC code: J05AJ01 | J05AR16 | J05AX08
SMILES: Cc1nnc(C(=O)NC(C)(C)c2nc(C(=O)NCc3ccc(F)cc3)c(O)c(=O)n2C)o1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 18
Group description: The raltegravir dosing will be 400mg twice daily by mouth. Subjects will continue all of their regular medications throughout the protocol.
Eligibility criteria:
Inclusion Criteria:

Capacity to provide informed consent.
Documented HIV-1 infection.
History of continuous cART treatment (with at least three drugs) for at least 2 years.
Documentation of 'undetectable' plasma HIV-1 RNA for at least 1 year.
HIV-1 RNA <50 copies/mL in plasma and CSF at screening visit.

Exclusion Criteria:

Contraindication to LP (suspicion of CNS mass lesion, bleeding diathesis, etc.).
Prior experience with raltegravir or contraindication to raltegravir treatment, including medication interactions that might compromise ongoing antiretroviral therapy or treatment of other conditions.
Active opportunistic infections or neurological diseases.
Other conditions or treatments likely to interfere with treatment or evaluation.
Hemoglobin < 10 Gm/dL.
Pregnant or anticipating pregnancy during study.
Active substance abuse.
Subjects taking rifampin, phenytoin, Phenobarbital or other drugs that accelerate raltegravir metabolism and might decrease its tissue concentrations.
Intervention: Duloxetine
Trial phase: Phase 4
ATC code: N06AX21
SMILES: CNCC[C@H](Oc1cccc2ccccc12)c1cccs1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 263
Group description: 60-120 mg, oral, daily, 12 weeks
Eligibility criteria:
Inclusion Criteria:

male or female patients
aged 18 and older who meet criteria for fibromyalgia as defined by the American College of Rheumatology
have a score of at least 4 on the average pain item of the Brief Pain Inventory (BPI) (modified short form) at visits 1 and 2
all females must test negative for pregnancy at the time of enrollment
have a degree of understanding such that the patient can provide informed consent, complete protocol required assessments and communicate intelligibly with the investigator and study coordinator.

Exclusion Criteria:

have pain symptoms related to traumatic injury, structural rheumatic disease, or regional rheumatic disease that will interfere with interpretation of outcome measures
have regional pain syndrome, multiple surgeries or failed back syndrome
have confirmed current or previous diagnosis of rheumatoid arthritis, inflammatory arthritis, or infectious arthritis, or an autoimmune disease (i.e. systemic lupus erythematosus)
Intervention: Varenicline
Trial phase: Not Applicable
ATC code: N07BA03 | S01XA28
SMILES: c1cnc2cc3c(cc2n1)C1CNCC3C1
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 19
Group description: Participants on this arm will receive varenicline tablets for 15 days.
Eligibility criteria:
Inclusion Criteria:

Regular smokers (currently >10 cigarettes/day; >5 pack years)
Willing to quit smoking for at least the duration of the study
Able and willing to give written informed consent

Exclusion Criteria:

Known condition causing endothelial dysfunction except smoking (i.e. diabetes, hyperlipi¬demia, arterial hypertension, obesity)
Regular drug treatment and/or sporadic consumption of drugs within the last 4 weeks (exclusion has to be decided in each individual)
Acute or chronic illness
Participation in clinical trial within 1 month before the study
Excessive daily intake of alcohol (>2 servings per day) or caffeine (>4 servings/day)
Drug and/or alcohol abuse.
Intervention: Choline Fenofibrate
Trial phase: Phase 1 | Phase 2
ATC code: C10AB11
SMILES: CC(C)(Oc1ccc(C(=O)c2ccc(Cl)cc2)cc1)C(=O)[O-].C[N+](C)(C)CCO
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 25
Group description: choline fenofibrate, 135 mg/day,orally, 12 weeks
Eligibility criteria:
Inclusion Criteria:

Male, non-smoker, 21 - 75 years of age inclusive.
Female, non-smoker, 40 - 75 years of age inclusive.
Post-menopausal women, as defined by lack of menses for at least 2 years and age > 55, OR history of documented bilateral surgical oophorectomy, confirmed with an elevated follicle-stimulating hormone (FSH) at screening.
HDL concentration (≤ 50 mg/dl women, ≤ 40mg/dl men)
TG concentration 150-500 mg/dl, inclusive
Ability to give informed consent

Exclusion Criteria:

Subject has history of diabetes mellitus, active hepatitis, gall bladder disease, gastric bypass surgery, or clinically significant abnormalities on screening (prestudy) physical examination or laboratory tests.
Screening laboratory tests with hematocrit <30%, aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2X upper limit of normal, abnormal thyroid-stimulating hormone (TSH), fasting glucose ≥126 mg/dl.
Renal impairment with creatinine clearance < 80 ml/min.
Treatment within the last 6 months with drugs known to alter lipid metabolism including beta blockers, thiazide diuretics, bile acid resins, ezetimibe, fibrates, niacin, and fish oils (see Appendix 1). Washout of fibrates is not permitted.
Treatment with drugs known to interact with ABT-335, e.g., warfarin (see Appendix 1).
Treatment with HMG CoA reductase inhibitors (statins) within the past 4 weeks (see Appendix 1).
History of allergy to egg or soy products.
History of coronary heart disease (CHD), stroke or revascularization procedure in the six months prior to Visit 1.
Current or recent history (past 12 months) of drug abuse or alcohol abuse. Alcohol abuse will be defined as >14 drinks per week (1 drink = 12 oz beer, 5 oz wine, or 1.5 oz hard liquor).
Participation in another clinical trial or exposure to any investigational agent within 30 days before visit 1.
Individual has a condition the Principal Investigator believes would interfere with his/her ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk.
Intervention: Sitagliptin
Trial phase: Not Applicable
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Glutamine 30 g/d (15 g with breakfast and dinner) + Sitagliptin
Eligibility criteria:
Inclusion Criteria:

Type 2 diabetes, on metformin or diet alone (not sulphonylureas or insulin)

Exclusion Criteria:

Malabsorption, renal or liver disease, treatment with steroids
Intervention: Cholecalciferol
Trial phase: Phase 2 | Phase 3
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 22
Group description: Placebo, two tablets daily in 52 weeks.
Eligibility criteria:
Inclusion Criteria:

P-Ca-ion > 1,30 mmol/l
P-PTH > 5 pmol/l
P-OH25-vitamin D < 80 nmol/l

Exclusion Criteria:

P-creatinin > 120 mumol/l
usage of Etalpha, Mimpara
Cancer
Sarcoidosis
malabsorption
pancreatitis
alcohol abuse
pregnancy
Intervention: Fluorodopa F-18
Trial phase: Phase 2
ATC code: V09IX05
SMILES: NC(Cc1cc(O)c(O)cc1F)C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 106
Group description: Obtain safety and efficacy data on the use of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET imaging in children with HI for the clinical indication of localizing a focal lesion

18 F-DOPA: 1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA
Eligibility criteria:
Inclusion Criteria:

Any age, but primarily infants 0-6 months.
Children with confirmed diagnosis of congenital hyperinsulinism.

Exclusion Criteria:

Cases in which surgery will not be considered by parents or guardians.
Intervention: Quetiapine
Trial phase: Phase 2
ATC code: N05AH04
SMILES: OCCOCCN1CCN(C2=Nc3ccccc3Sc3ccccc32)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 81
Group description: Seroquel

Seroquel: 400 mg/day
Eligibility criteria:
Inclusion Criteria:

Male and females, 18-70 years old.
Meets DSM-IV criteria for current diagnoses of alcohol dependence, determined by the MINI/SCID-IV {First, 1996 #34}.
Meets the drinking criteria, measured by TLFB and the Addiction Severity Index {McLellan, 1992 #37}:
Three consecutive days of abstinence from alcohol immediately before randomization
Lives a commutable distance from the TRC and agrees to attend all research visits including follow-up visits.
Speaks, understands, and prints in English.

Exclusion Criteria:

Has evidence of dependence on a substance other than alcohol (except nicotine and marijuana).
Tests positive on the urine drug screen during the screening weeks (one retest allowed). Subjects whose urine drug screen tests positive for benzodiazepines will be allowed to randomize, at the discretion of the PI, if they are known to be physician-prescribed for detox purposes.
Has hepatocellular disease indicated by elevations of SGPT (ALT) and SGOT (AST) of at least 4.5 times normal after the required 3 days of abstinence, or elevated bilirubin (>1.3), with associated elevations of AST and ALT above normal limits.

Meets diagnostic criteria for a current unstable or serious psychiatric or medical illness.

Has serious heart, lung, kidney, immune system, GI tract (ulcerative colitis, regional enteritis, or gastrointestinal bleeding) disease.

Has taken any psychotropic medications (including disulfiram, naltrexone or acamprosate) regularly within the last 2 weeks or needs immediate treatment with a psychotropic medication.
Tests positive on a pregnancy test, is contemplating pregnancy in the next 12 months, is nursing, or is not using an effective contraceptive method if the patient is of child-bearing potential, meaning has not had a hysterectomy or is in menopause, meaning 50 or over and has not had a menstrual cycle in 12 months.
Has known hypersensitivity to antipsychotics.
Has taken any investigational drug as part of an investigational trial within 30 days prior to the randomization.
A history of seizure disorder.
The presence of cataracts.
Intervention: Erlotinib
Trial phase: Phase 2
ATC code: L01EB02 | L01XE03
SMILES: C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCOC)cc23)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 104
Group description: Participants with advanced pancreatic carcinoma with ECOG PS score of 0 to 2, who had failed 1 prior regimen of chemotherapy or who were considered unsuitable for chemotherapy, received erlotinib 150 mg orally once daily until PD, unacceptable toxicity, withdrawal, or death.
Eligibility criteria:
Inclusion Criteria:

adult patients, >=18 years of age;
histologically or cytologically documented locally advanced-unresectable or metastatic pancreatic cancer;
measurable disease according to RECIST;
failure of at least one prior chemotherapy regimen, or who are deemed unsuitable for chemotherapy;
ECOG performance status of 0-2.

Exclusion Criteria:

local or locally advanced-resectable pancreatic cancer;
any other malignancies within last 5 years, except for adequately treated cancer in situ of the cervix, or basal or squamous cell skin cancer;
major surgery within 2 weeks prior to randomization.